Cardeas Pharma, a US-based drugs maker developing antibiotics, has raised $34m in its series B round from a consortium including Denmark-based peer Novo. Venture capital firms HIG BioVentures, which led the B roundAvalon Ventures, Delphi Ventures and Devon Park Bioventures and Washington Research Foundation’s WRF Capital joined HIG in the consortium. In June last year,…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
